Semaglutide induced Pancreatitis

Author(s)	Princy R
Country	India
Abstract	Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for managing type 2 diabetes due to its efficacy in enhancing insulin secretion and facilitating weight loss. Despite its benefits, concerns have arisen regarding the potential risk of acute pancreatitis (AP) associated with GLP-1 RA use. Although the Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial did not show a significant increase in AP risk with semaglutide, some studies indicate a possible link between GLP-1 RAs and pancreatic inflammation. This case is about a patient with AP who was recently started on semaglutide. The increasing use of GLP-1 RAs necessitates awareness of their potential to cause pancreatic complications, underscoring the need for ongoing research and clinical vigilance to better understand and manage this risk.
Keywords	Semaglutide, Pancreatitis, Glucagon-like peptide-1 receptor agonist
Field	Medical / Pharmacy
Published In	Volume 6, Issue 4, July-August 2024
Published On	2024-08-19
Cite This	Semaglutide induced Pancreatitis - Princy R - IJFMR Volume 6, Issue 4, July-August 2024. DOI 10.36948/ijfmr.2024.v06i04.26238
DOI	https://doi.org/10.36948/ijfmr.2024.v06i04.26238
Short DOI	https://doi.org/gt7m43

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9898-5948-55	editor@ijfmr.com

International Journal For Multidisciplinary Research